[go: up one dir, main page]

PL2187882T3 - Leczenie postępującej choroby neurodegeneracyjnej ibudilastem - Google Patents

Leczenie postępującej choroby neurodegeneracyjnej ibudilastem

Info

Publication number
PL2187882T3
PL2187882T3 PL08781498T PL08781498T PL2187882T3 PL 2187882 T3 PL2187882 T3 PL 2187882T3 PL 08781498 T PL08781498 T PL 08781498T PL 08781498 T PL08781498 T PL 08781498T PL 2187882 T3 PL2187882 T3 PL 2187882T3
Authority
PL
Poland
Prior art keywords
ibudilast
treatment
neurodegenerative disease
progressive neurodegenerative
progressive
Prior art date
Application number
PL08781498T
Other languages
English (en)
Inventor
Michael E Kalafer
Kenneth W Locke
Kazuko Matsuda
Richard E Gammans
Original Assignee
Medicinova Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medicinova Inc filed Critical Medicinova Inc
Publication of PL2187882T3 publication Critical patent/PL2187882T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PL08781498T 2007-07-11 2008-07-08 Leczenie postępującej choroby neurodegeneracyjnej ibudilastem PL2187882T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US92974507P 2007-07-11 2007-07-11
US4218108P 2008-04-03 2008-04-03
EP08781498A EP2187882B1 (en) 2007-07-11 2008-07-08 Treatment of progressive neurodegenerative disease with ibudilast
PCT/US2008/069417 WO2009009529A1 (en) 2007-07-11 2008-07-08 Treatment of progressive neurodegenerative disease with ibudilast

Publications (1)

Publication Number Publication Date
PL2187882T3 true PL2187882T3 (pl) 2013-05-31

Family

ID=39789775

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08781498T PL2187882T3 (pl) 2007-07-11 2008-07-08 Leczenie postępującej choroby neurodegeneracyjnej ibudilastem

Country Status (14)

Country Link
US (10) US8138201B2 (pl)
EP (2) EP2567699A1 (pl)
JP (2) JP5468001B2 (pl)
CN (1) CN101848712B (pl)
AU (1) AU2008275148A1 (pl)
BR (1) BRPI0814624A2 (pl)
CA (2) CA2693697C (pl)
DK (1) DK2187882T3 (pl)
ES (1) ES2402175T3 (pl)
HR (1) HRP20130057T1 (pl)
PL (1) PL2187882T3 (pl)
PT (1) PT2187882E (pl)
TW (1) TW200918051A (pl)
WO (1) WO2009009529A1 (pl)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2442651T3 (en) * 2009-06-19 2015-09-21 Teva Pharma Treatment of multiple sclerosis with laquinimod
US8119657B2 (en) 2009-06-23 2012-02-21 Medicinova, Inc. Enantiomeric compositions of 2-amino-1-(2-isopropylpyrazolo[1,5-α]pyridin-3-yl)propan-1-one and related methods
CN105616410A (zh) * 2009-07-30 2016-06-01 泰华制药工业有限公司 利用拉喹莫德治疗克隆氏病
PL2467372T3 (pl) * 2009-08-10 2017-04-28 Teva Pharmaceutical Industries Ltd. Leczenie zaburzeń związanych z BDNF z zastosowaniem lakwinimodu
PT3536333T (pt) * 2010-01-04 2022-11-11 Mapi Pharma Ltd Sistema de depósito compreendendo acetato de glatirâmero
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
KR20130014523A (ko) * 2010-03-03 2013-02-07 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드 및 메토트렉세이트의 병용에 의한 류마티스 관절염의 치료
PH12012501741A1 (en) * 2010-03-03 2012-11-12 Teva Pharma Treatment of lupus arthritis using laquinimod
KR20130006640A (ko) * 2010-03-03 2013-01-17 테바 파마슈티컬 인더스트리즈 리미티드 라퀴니모드를 이용한 루푸스 신장염의 치료
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
CA2851525A1 (en) 2011-10-12 2013-04-18 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with combination of laquinimod and fingolimod
EP2811832A4 (en) 2012-02-03 2015-09-23 Teva Pharma USE OF LAQUINIMOD FOR THE TREATMENT OF PATIENTS WITH MORBUS CROHN AFTER FAILED PREVIOUS ANTI-TNF THERAPY
CN103255142B (zh) * 2012-02-21 2017-07-25 上海转基因研究中心 一种利用RNAi调控内源性朊蛋白表达的方法及其应用
TW201400117A (zh) 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
CN103505731A (zh) * 2012-06-15 2014-01-15 中国药科大学 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途
FR3000746A1 (fr) 2013-01-04 2014-07-11 Centre Nat Rech Scient Peptide pour son utilisation dans le traitement des neuronopathies motrices
WO2014127139A1 (en) * 2013-02-15 2014-08-21 Teva Pharmaceutical Industries Ltd. Treatment of multiple sclerosis with laquinimod
WO2014178892A1 (en) 2013-05-03 2014-11-06 Scanlan Thomas S Use of sobetirome in the treatment of x-linked adrenolenoleukodystrophy
CN106573014A (zh) 2014-04-29 2017-04-19 梯瓦制药工业有限公司 用于治疗具有高残疾状况的复发‑缓解型多发性硬化症(rrms)的患者的拉喹莫德
US20150366847A1 (en) * 2014-06-20 2015-12-24 Medicinova, Inc. Combination of geranylgeranylacetone and ibudilast and methods of using same
CA2961187A1 (en) * 2014-09-16 2016-03-24 Teva Pharmaceuticals Industries Ltd. Treatment of neurodegenerative diseases with combination of laquinimod and fingolimod
WO2016086000A1 (en) * 2014-11-26 2016-06-02 Medicinova, Inc. A combination of geranygeranylacetone, ibudilast, and riluzole and methods of using same
US10258611B2 (en) 2014-11-26 2019-04-16 Medicinova, Inc. Combination of ibudilast and riluzole and methods of using same
CN105395511A (zh) * 2015-12-07 2016-03-16 黑龙江省智诚医药科技有限公司 一种异丁司特缓释微丸及其制备方法
EP3454853B1 (en) * 2016-05-10 2022-05-18 MediciNova, Inc. Treatment of alcoholism and depression using ibudilast
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
WO2018119262A1 (en) * 2016-12-22 2018-06-28 Medicinova, Inc. Methods of treating glioblastoma multiforme using ibudilast
WO2018178973A1 (en) 2017-03-26 2018-10-04 Mapi Pharma Ltd. Glatiramer depot systems for treating progressive forms of multiple sclerosis
ES2959799T3 (es) * 2018-02-12 2024-02-28 Medicinova Inc Métodos para suprimir células supresoras de origen mieloide en pacientes
JP2021512921A (ja) 2018-02-12 2021-05-20 メディシノバ・インコーポレイテッドＭｅｄｉｃｉＮｏｖａ， Ｉｎｃ． 癌療法に対するイブジラストおよび第二の薬剤を使用した方法ならびに投与レジメン
EP3863628B1 (en) * 2018-10-09 2023-12-27 MediciNova, Inc. Combination of ibudilast and interferon-beta and methods of using same
JP7430719B2 (ja) * 2018-10-19 2024-02-13 メディシノバ・インコーポレイテッド イブジラストを用いて眼疾患／障害または損傷を治療する方法
CA3122996A1 (en) 2018-12-12 2020-06-18 Autobahn Therapeutics, Inc. Novel thyromimetics
WO2020176445A1 (en) * 2019-02-26 2020-09-03 Universitat De Valencia-Estudi General Methods and compositions for treating motor neuron diseases
JP7503560B2 (ja) 2019-03-01 2024-06-20 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
WO2020251748A1 (en) * 2019-06-11 2020-12-17 Yale University Novel treatment for wolfram syndrome
JP7652763B2 (ja) 2019-09-23 2025-03-27 メディシノバ・インコーポレイテッド イブジラスト経口製剤およびその使用方法
WO2021207054A1 (en) 2020-04-06 2021-10-14 Medicinova, Inc. Methods of reducing plasma level of macrophage migratory inhibitory factor in patients with ibudilast
CA3206115A1 (en) 2021-01-29 2022-08-04 Kazuko Matsuda Methods of treating chemical gas exposure
EP4376838A1 (en) 2021-07-26 2024-06-05 MediciNova, Inc. Ibudilast for preventing eye cancer metastasis
JP2024535880A (ja) 2021-09-21 2024-10-02 メディシノバ・インコーポレイテッド 膠芽腫の治療における使用のための併用療法におけるイブジラスト
US12042485B2 (en) 2021-10-07 2024-07-23 Medicinova, Inc. Methods of minimizing cancer metastasis
EP4472631A1 (en) 2022-02-01 2024-12-11 MediciNova, Inc. Ibudilast for use in the treatment of post-covid conditions
WO2023192885A2 (en) * 2022-03-28 2023-10-05 Praxis Precision Medicines, Inc. Methods of using oligomeric compounds to treat scn2a-related disorders
US20240016729A1 (en) 2022-07-13 2024-01-18 Medicinova, Inc. Injectable formulations of ibudilast

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1106178B1 (en) 1998-08-10 2004-11-24 Kyorin Pharmaceutical Co., Ltd. Use of ibudilast for the manufacture of a medicament for treating multiple sclerosis
EP1343528A2 (en) 2000-11-02 2003-09-17 Research Foundation of City University of New York Methods for stimulating nervous system regeneration and repair by inhibition phosphodiesterase type 4
US20050043319A1 (en) * 2001-08-14 2005-02-24 Exonhit Therapeutics Sa Molecular target of neurotoxicity
WO2005051293A2 (en) 2003-11-21 2005-06-09 Combinatorx, Incorporated Methods and reagents for the treatment of inflammatory disorders
BRPI0518829A2 (pt) 2004-12-06 2008-12-09 Avigen Inc mÉtodo para o tratamento de dor neuropÁtica e sÍndromes associadas
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節

Also Published As

Publication number Publication date
HRP20130057T1 (hr) 2013-02-28
US8338453B2 (en) 2012-12-25
PT2187882E (pt) 2013-04-17
US20200093805A1 (en) 2020-03-26
US20120214839A1 (en) 2012-08-23
EP2567699A1 (en) 2013-03-13
US20150011581A1 (en) 2015-01-08
JP2010533193A (ja) 2010-10-21
US11944607B2 (en) 2024-04-02
US11083713B2 (en) 2021-08-10
US20090062330A1 (en) 2009-03-05
CN101848712A (zh) 2010-09-29
CA2970273A1 (en) 2009-01-15
CA2693697A1 (en) 2009-01-15
US9314452B2 (en) 2016-04-19
WO2009009529A1 (en) 2009-01-15
DK2187882T3 (da) 2013-04-08
EP2187882A1 (en) 2010-05-26
CN101848712B (zh) 2013-07-24
US20130217718A1 (en) 2013-08-22
US8138201B2 (en) 2012-03-20
CA2970273C (en) 2020-04-14
US9114136B2 (en) 2015-08-25
JP5468001B2 (ja) 2014-04-09
US20170014390A1 (en) 2017-01-19
AU2008275148A1 (en) 2009-01-15
CA2693697C (en) 2017-07-25
JP2014062118A (ja) 2014-04-10
US20170020851A1 (en) 2017-01-26
BRPI0814624A2 (pt) 2015-01-27
EP2187882B1 (en) 2013-01-09
US20140171463A1 (en) 2014-06-19
ES2402175T3 (es) 2013-04-29
US20220168283A1 (en) 2022-06-02
US20250073213A1 (en) 2025-03-06
TW200918051A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
PL2187882T3 (pl) Leczenie postępującej choroby neurodegeneracyjnej ibudilastem
HK1211889A1 (en) Therapeutic use of diaminophenothiazines
GB0813740D0 (en) Therapeutic compounds
GB0806794D0 (en) Therapeutic compounds
GB2464440B (en) Massager
GB0908193D0 (en) Treatment of disease state
GB0804755D0 (en) Therapeutic compounds
ZA201202346B (en) Therapeutic agent for mood disorders
GB0700972D0 (en) Treatment of inflammatory disease
GB0715790D0 (en) Drug combination for the treatment of sialorrhoea
GB0720976D0 (en) Treatment of inflammatory disease
GB0809476D0 (en) Treatment of neurodegenerative disorders
GB0723100D0 (en) Treatment of HFnEF
EP2212701A4 (en) NEW TREATMENT OF AUTOIMMUNE DISEASES
GB0906026D0 (en) Therapeutic compounds
GB0817859D0 (en) Treatment of proteostatic disease
GB0819543D0 (en) Treatment of proteostatic disease
GB0701350D0 (en) Therapeutic invention
GB0919113D0 (en) Therapeutic invention
GB0908666D0 (en) Treatment of proteostatic disease
GB0907254D0 (en) Combating disease
GB0818712D0 (en) Therapeutic substances
GB0812816D0 (en) Therapeutic substances
GB0810952D0 (en) Therapeutic substances
GB0804377D0 (en) Therapeutic substances